The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report
Open accessAbstract
Background: Many patients with major depressive disorder (MDD) who experience full symptomatic remission after antidepressant treatment still have residual depressive symptoms. We describe the types and frequency of residual depressive symptoms and their relationship to subsequent depressive relapse after treatment with citalopram in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Method: Participants in primary ( n =18) and psychiatric ( n =23) practice settings were openly treated with citalopram using measurement-based care for up to 14 weeks and follow-up for up to 1 year. We assessed 943 (32.8% of 2876) participants who met criteria for remission to determine the proportions with individual residual symptoms and any of the nine DSM-IV criterion symptom domains to define a major depressive episode. At each visit, the 16-item Quick Inventory of Depressive Symptomatology, Self-Report (QIDS-SR 16 ) and the self-report Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) scale were used to assessed depressive symptoms and side-effects respectively. Results: More than 90% of remitters had at least one residual depressive symptom (median=3). The most common were weight increase (71.3%) and mid-nocturnal insomnia (54.9%). The most common residual symptom domains were sleep disturbance (71.7%) and appetite/weight disturbance (35.9%). Those who remitted before 6 weeks had fewer residual symptoms at study exit than did later remitters. Residual sleep disturbance did not predict relapse during follow-up. Having a greater number of residual symptom domains was associated with a higher probability of relapse. Conclusions: Patients with remission of MDD after treatment with citalopram continue to experience selected residual depressive symptoms, which increase the risk of relapse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Less ill patients are known to have a smaller relapse risk overall (e.g. Nierenberg et al. 2010)”
From Predicting relapse after antidepressant withdrawal – a systematic review (2017) · cites this paper as Nierenberg et al. 2010
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The foregoing cascade approach - which in tegrates aspects of misdiagnosis, non- ad herence, inadequate treatment trials, as well as implementation gaps - underscores the high prevalence of poor outcomes of depression in primary care, of which a significant percentage would be expected to meet crite ria for TRD 10,30,64,71,107,108 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [71]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Residual symptom load affects relapse risk overall (Nierenberg et al. 2010)”
From Predicting relapse after antidepressant withdrawal – a systematic review (2017) · cites this paper as Nierenberg et al. 2010
The cited source says what the claim attributes to it.
In the citing paper
“This was highlighted in the STAR * D trial, in which it was ob served that only 10% of persons 'in re mission' were fully asymptomatic 71 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [71]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Further drawbacks of existing TRD defi nitions are that they fail to take into consid eration the social, economic, anamnestic (e.g., adverse childhood experiences) and interpersonal factors which, alone or in combinations, are known to moderate antidepressant response 1,44,47,71,75- 81 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [71]
Experimental — accuracy not yet measured
In the citing paper
“They increase the risk for [10] and seem to be a prodromal symptom of relapse [11].”
From The effects of exercise on sleep in unipolar depression: a systematic review and network meta-analysis (2021) · cites this paper as [10]
In the citing paper
“A higher number of previous episodes (Berwian, Walter, Seifritz, & Huys, 2017; Kendler, Thornton, & Gardner, 2000), more residual symptoms (Berwian et al., 2017; Nierenberg et al., 2010), and failure to reach remission after acute antidepressant treatment (APA, 2010; Rush et al., 2006) are associated with a greater risk of relapse”
From Relapse prevention with levomilnacipran ER in adults with major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study (2019) · cites this paper as Nierenberg et al., 2010
In the citing paper
“In addition, patients who had residual depression symptoms despite responding to treatment, had higher risk of recurrence (Serafini et al., 2018; Nierenberg et al., 2010; Judd et al., 1998) [19, 24, 25].”
From Predictors of recurrence of major depressive disorder (2020) · cites this paper as Nierenberg et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Development of a Rating Scale for Primary Depressive Illness
Hamilton, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Self-citationRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Self-citationSequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076
Self-citationTRIVEDI, M. H., RUSH, A. J., IBRAHIM, H. M., CARMODY, T. J., BIGGS, M. M., SUPPES, T., CRISMON, M. L., SHORES-WILSON, K., TOPRAC, M. G., DENNEHY, E. B., et al. (2004) · Psychological Medicine · doi:10.1017/s0033291703001107 · Cited by 968 · cited 2×
“…(HAMD17 ; Hamilton, 1960, 1967) or f5 on the 16-item Quick Inventory of Depressive Symptomatology, SelfReport (QIDS-SR16 ; Rush et al. 2003, 2006a ; Trivedi et al. 2004) or response (typically defined as 50% improvement in depression rating scale scores) have been associated with continued…”
BackgroundMethodSelf-citationJudd, L. L., Akiskal, H. S., Maser, J. D., Zeller, P. J., Endicott, J., Coryell, W., Paulus, M. P., Kunovac, J. L., Leon, A. C., Mueller, T. I., et al. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.8.694 · Cited by 775
Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301131 · Cited by 707 · cited 3×
“Remission was defined as a score f5 on the 16-item Quick Inventory of Depressive Symptomatology, Clinician-rated (QIDS-C16 ; Rush et al. 2003, 2006a ; Trivedi et al. 2004).”
BackgroundMethodSelf-citationJudd, L. L., Akiskal, H. S., Maser, J. D., Zeller, P. J., Endicott, J., Coryell, W., Paulus, M. P., Kunovac, J. L., Leon, A. C., Mueller, T. I., et al. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00138-4 · Cited by 590
Treatments of Depression and the Functional Capacity to Work
Mintz, J. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820100005001 · Cited by 561
Cited by
Sorted by citations
Items 401–456 of 456
Emotionale Verflachung unter antidepressiver Therapie
Landgrebe, M., & Hajak, G. (2015) · DNP - Der Neurologe und Psychiater · doi:10.1007/s15202-015-0817-2
Glutamate Approaches Towards the Treatment of Mood Disorders
Jones, C. K., Conn, P. J., & Lindsley, C. W. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734943-00258
Individualized Treatment of Depression
(2013) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814343664_0010
Olié, É., Courtet, P., & Clés, M. (2010)
Lawford‐Smith, H. (2015)
Which therapy for which patient?
Greer, T. L., Kurian, B. T., & Trivedi, M. H. (2012) · doi:10.2217/ebo.11.299
Self-citationTreating depression with activation
Nyström, M. B. T. (2018) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Zelfhulp om terugval in een depressie te voorkomen
Biesheuvel-Leliefeld, K. E. M., Dijkstra‐Kersten, S. M. A., van Schaik, A., van Marwijk, H., Smit, F., van der Horst, H. E., & Bockting, C. (2018) · Huisarts en Wetenschap · doi:10.1007/s12445-018-0299-5
Kim, K., Yoo, I., Woo, J., Lee, S., D, M. F. M., Mischoulon, D., Papakostas, G. I., Kim, E.-J., Chung, S. H., Ha, J. H., et al. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw043.089
Understanding the role of symptoms of sleep disturbance in suicidal pathways
Littlewood, D. L. (2018) · Research Explorer (The University of Manchester)
Michelon, L. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2019.tde-25102019-131555
Mood Stabilizers: Classification, Indications and Differential Indications
Menke, A. (2020) · Springer eBooks · doi:10.1007/978-3-319-56015-1_36-1
Poirot, I., Brion, A., Schroder, C. M., & Touitou, Y. (2016) · Dunod eBooks · doi:10.3917/dunod.schro.2016.01.0089 · Cited by 1
Residual symptoms of depression and their importance in common clinical practice
Češková, E. (2020) · Psychiatrie pro praxi · doi:10.36290/psy.2020.011
Personalized treatment strategies for depression
van Bronswijk, S. C. (2020) · Research Publications (Maastricht University) · doi:10.26481/dis.20201211sb
Impact of psychological disorders
Carney, C. E., Moss, T. G., & Carney, A. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822963-7.00074-8
Riesgo suicida y recaída en el consumo de sustancias psicoactivas: Una revisión sistemática
Zeas, J. P. S., Ortiz, G., & Suarez, P. (2021) · South Florida Journal of Development · doi:10.46932/sfjdv2n2-144
Harvey, A. G., & Gasperetti, C. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822872-2.00007-4
Analysis of Classes Used in the Treatment of Depression by Physician-reported Severity.
Lenderts, S., Kalali, A. H., & Weisler, R. H. (2010) · PubMed Central
Current awareness in human psychopharmacology
(2010) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1063
Primeau, M. M., Tal, J. Z., & O'Hara, R. M. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2089-1_38
Lifestyle Factors on Depression, Effects of
Lo, A. H. Y. (2017) · Springer eBooks · doi:10.1007/978-981-287-082-7_279
Guroo, M. A. A., Nabi, J., & Shaban, S. (2022) · PARIPEX-INDIAN JOURNAL OF RESEARCH · doi:10.36106/paripex/0201352
Mood Stabilizers: Classification, Indications and Differential Indications
Menke, A. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_36
Antidepressants: Indications, Contraindications, Interactions, and Side Effects
Corponi, F., Fabbri, C., & Serretti, A. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_29
Borentain, S., McCormick, C. D., Joshi, K., O’Hara, M., Zhang, Q., Mulhern-Haughey, S., Richards, S., Anjo, J., Zante, D., Kewley, R. M., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2138354/v1
Trajectories of Depressive Individual Symptoms over Time during Transcranial Photobiomodulation
Urata, M., Cassano, P., Norton, R., Sylvester, K. W., Watanabe, K., Iosifescu, D. V., & Sakurai, H. (2023) · Photonics · doi:10.3390/photonics10121324
Effect of Non-Invasive Brain Stimulation on Sleep and Sleep Disorders
Byun, J., Shin, W. C., & Jung, K. (2023) · Journal of Sleep Medicine · doi:10.13078/jsm.230027
Takeshima, M., Umakoshi, A., Omori, Y., Yoshizawa, K., Ogasawara, M., Kudo, M., Itoh, Y., Ayabe, N., & Mishima, K. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06581-1
Brain Age Is Not a Significant Predictor of Relapse Risk in Late-Life Depression
Karim, H. T., Gerlach, A., Butters, M. A., Krafty, R. T., Boyd, B. D., Banihashemi, L., Landman, B. A., Ajilore, O., Taylor, W. D., & Andreescu, C. (2024) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2024.09.009 · Cited by 1
Sleep and Psychiatric Disorders
Manber, R., Dietch, J. R., Gumport, N. B., & Simpson, N. S. (2025) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780197602751.013.28
Effects of Cognitive Therapy for Depression on Insomnia in Women with Metastatic Breast Cancer
Brearty, C. M., & Savard, J. (2025) · Behavioral Sleep Medicine · doi:10.1080/15402002.2025.2549550
Research Progress on Acupuncture for the Treatment of Depression-Related Insomnia
刘, 亚. (2025) · Traditional Chinese Medicine · doi:10.12677/tcm.2025.1410604
Kong, Z., Zhu, X., 常, 素., Bao, Y., Ma, Y., Yu, W., Zhu, R., Sun, Q., Sun, W., Deng, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22607828
Wang, Q., Hu, S., Qi, L., Wang, X., Jin, G., Wu, D., Wang, Y., & Ren, L. (2024) · Figshare · doi:10.6084/m9.figshare.24234300
Richieri, R. M. (2014) · theses.fr (ABES) · doi:10.70675/5d3af1abz1fd4z4313za06ez97c949a8fb85
Hwang, D.-J., & Cho, J. (2026) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00091.2026
Piksa, M., Cieslik-Starkiewicz, A., & Ryguła, R. (2026) · Psychopharmacology · doi:10.1007/s00213-026-07060-5
Yang, L., Yan, P., Xu, Y., Hu, L., Wei, J., Song, M., Liu, W., & Mao, H. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-08060-7
Cai, H., Chen, P., Sun, H., Zhang, Q., Li, X.-H., Su, Z., Cheung, T. C. C., Ungvari, G. S., Ng, C. H., Zhang, L., et al. (2026) · Asia-Pacific Psychiatry · doi:10.1111/appy.70023
Borghgraef, D., Sienaert, P. A., & Lambrichts, S. (2026) · The Canadian Journal of Psychiatry · doi:10.1177/07067437261448747
Kwaśny, A., Wilkowska, A., Pastuszak, M., Pastuszak, K., & Cubała, W. J. (2026) · Pharmacological Reports · doi:10.1007/s43440-026-00867-1
Oe, Y., Kurihara, M., Hayasaka, T., Nagashima, I., Murao, M., Matsumoto, Y., Takaesu, Y., Tsuboi, T., Watanabe, K., & Sakurai, H. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1838340
Higson‐Sweeney, N., Dunn, B. D., Marshall, N., Cooper, K., Reynolds, S. A., Goodyer, I. M., & Loades, M. E. (2026) · BMC Psychology · doi:10.1186/s40359-026-04942-3
A Pragmatic Algorithm for Selecting Psychopharmacology Treatment for Secondary Insomnia
Chen, A. C. N., Taj, F., Fonseka, L. N., & Osser, D. N. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002219
Schneeberger, A. R., Robinett, J., Harlé, K. M., Lasswell, E., Duarte, K. L., Clark, A. L., Bhakta, S. G., Thackaberry, J., & Lee, K. C. (2026) · Psychiatric Research and Clinical Practice · doi:10.1176/appi.prcp.20250158
Residual depression symptoms following nature-based exercise therapies among U.S. service members
Otis, N. P., Glassman, L. H., Kline, A. C., Elliott, K. T. K., Michalewicz-Kragh, B., & Walter, K. H. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1788999
吴, 邢. (2026) · Traditional Chinese Medicine · doi:10.12677/tcm.2026.158462
Liu, Y., Santos, B. D. L., Kim, M., Manne, S., Gandhi, V., Lü, M., & Martin, M. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122429
Zhang, J., Wang, W., Wang, F., Liu, Y., He, D., & Liu, L. (2026) · Research Square · doi:10.21203/rs.3.rs-10507626/v1
Residual daytime sleepiness in depression: The blob framework
Geoffroy, P. A., Maruani, J., Quilès, C., & Micoulaud‐Franchi, J. (2026) · L Encéphale · doi:10.1016/j.encep.2026.08.001
Hamilton, J. M., Pain, É., Riise, J., & Zhang, Z. (2026) · Interactive Journal of Medical Research · doi:10.2196/93231
Takahashi, S., Eto, M., Hata, M., Shinosaki, K., & Ikeda, M. (2026) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.70404
Kato, M., Baba, T., Sonoyama, T., & Iwata, N. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1891881
Metadata
- Authors
- Nierenberg, A. A., Husain, M. M., Trivedi, M. H., Fava, M., Warden, D., Wisniewski, S. R., Miyahara, S., & Rush, A. J.
- Affiliations
- Massachusetts General Hospital (US)
- The University of Texas Southwestern Medical Center (US)
- University of Pittsburgh (US)
- Corresponding author
- Nierenberg, A. A.
- Venue
- Psychological Medicine
- Publisher
- Cambridge University Press (CUP)
- Published
- 2009-05-22
- Volume
- 40
- Issue
- 1
- Pages
- 41-50
- ISSN
- 0033-2917 (ISSN-L)
- 1469-8978
- PMC
- PMC5886713
- OpenAlex
- W2150325627
- Cited by
- 458
- References
- 31
- Citations by year
- 2026: 24 · 2025: 23 · 2024: 23 · 2023: 32 · 2022: 35 · 2021: 23 · 2020: 26 · 2019: 34 · 2018: 26 · 2017: 24 · 2016: 25 · 2015: 31 · 2014: 28 · 2013: 34 · 2012: 30
- FWCI
- 16.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Psychological Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Health and Human Services
- Bristol-Myers Squibb
- University of Texas Southwestern Medical Center
- National Institutes of Health (n01mh90003-26-0-0)
- National Institute of Mental Health (N01 MH090003)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- major depressive disorder, residual depressive symptoms, remission, citalopram, relapse risk, sleep disorders, weight gain, antidepressant side effects, STAR*D trial, QIDS-SR16
- MeSH terms
- Adult, Major Depressive Disorder, Female, Follow-Up Studies, Humans, Sleep Initiation and Maintenance Disorders, Male, Middle Aged, Personality Inventory, Psychometrics, Recurrence, Risk Factors, Citalopram, Weight Gain, Cognitive Behavioral Therapy, Antidepressive Agents, Second-Generation, Kaplan-Meier Estimate, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
